Pre Clinical And Clinical Drug Development Articles & Analysis
7 articles found
Alfa Cytology unveils advanced PD-1 inhibitor development service for cancer research. Alfa Cytology, a prominent service provider in the oncology landscape, has recently launched its innovative PD-1 inhibitor development services. This initiative marks a significant advancement in the quest for more effective cancer therapies, focusing on enhancing precision and adaptability in treatment ...
Alfa Cytology unveils advanced cancer immunotherapy development services. Alfa Cytology, a renowned services supplier in oncology, has recently introduced its groundbreaking cancer immunotherapy development services. This initiative signifies a major leap forward in the development of more effective cancer therapies, aiming to boost both precision and versatility within treatment paradigms. ...
The evaluation of cardiovascular toxicity is a significant challenge in drug development. Preclinical evaluation of cardiovascular safety involves a multifaceted approach, encompassing a plethora of in vitro and in vivo endpoints. These assessments continuously evolve, aiming to mitigate the incidence of cardiovascular toxicity that may emerge during clinical trials. To shed light on the ...
Alfa Cytology has unveiled new services focused on therapeutic antibody development for bladder cancer research.Alfa Cytology, a prominent cancer research services supplier based in New York, proudly announces the launch of its comprehensive services for bladder cancer therapeutic antibody development. This initiative represents a critical advancement in pursuing effective bladder cancer ...
In the world of pharmaceuticals, developing safe and effective drugs is a complex and time-consuming process. Before a new drug candidate can progress to clinical trials and ultimately reach the market, it needs to undergo rigorous testing in various model systems to assess its efficacy and safety. One critical component of this evaluation is the use of preclinical animal models. Preclinical ...
The clinical presentation of COVID-19-related illness ranges from asymptomatic to mild respiratory symptoms resembling influenza infection to acute symptoms including pneumonia requiring hospitalization and admission to the intensive care unit. COVID-19 starts in the upper airways and lungs, but in severe cases can also affect the heart, blood vessels, brain, liver, kidneys, and intestines. ...
Prediction of the first-in-human dosing regimens is a critical step in drug development and requires accurate quantitation of drug distribution. Traditional in vivo studies used to characterize clinical candidate’s volume of distribution are error-prone, time and cost intensive and lack reproducibility in clinical settings. The paper demonstrates how a computational platform integrating ...